Impaired IL-10 transcription and release in animal models of Gaucher disease macrophages

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 1, 2009, Pages 134-137

  Kacher, Yaacov ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Gaucher disease; Interleukin 10; Macrophages; TNF

Indexed keywords

GLUCOSYLCERAMIDASE; INTERLEUKIN 10; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; GAUCHER DISEASE; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; CELLS, CULTURED; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; INOSITOL; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 68649108116     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.03.006     Document Type: Article

References (33)

1. Futerman A.H., and Zimran A. Gaucher Disease (2006), Taylor and Francis Group, Boca Raton
2. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Sly W.S., Childs B., Beaudet A.L., Valle D., Kinzler K.W., and Vogelstein B. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill Inc. 3635-3668
3. Kacher Y., and Futerman A.H. Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options. FEBS Lett. 580 (2006) 5510-5517
4. Jmoudiak M., and Futerman A.H. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129 (2005) 178-188
5. Futerman A.H., and van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev., Mol. Cell Biol. 5 (2004) 554-565
6. Castaneda J.A., Lim M.J., Cooper J.D., and Pearce D.A. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 115 (2008) 159-174
7. Jeyakumar M., Thomas R., Elliot-Smith E., Smith D.A., van der Spoel A.C., d'Azzo A., Perry V.H., Butters T.D., Dwek R.A., and Platt F.M. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126 (2003) 974-987
8. Barak V., Acker M., Nisman B., Kalickman I., Abrahamov A., Zimran A., and Yatziv S. Cytokines in Gaucher's disease. Eur. Cytokine Network 10 (1999) 205-210
9. Hollak C.E., Evers L., Aerts J.M., and van Oers M.H. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol. Dis. 23 (1997) 201-212
10. Allen M.J., Myer B.J., Khokher A.M., Rushton N., and Cox T.M. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 90 (1997) 19-25
11. Lichtenstein M., Zimran A., and Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol. Dis. 23 (1997) 395-401
12. Boven L.A., van Meurs M., Boot R.G., Mehta A., Boon L., Aerts J.M., and Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 122 (2004) 359-369
13. Legler G., and Bieberich E. Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F. Arch. Biochem. Biophys. 260 (1988) 437-442
14. Mizukami H., Mi Y., Wada R., Kono M., Yamashita T., Liu Y., Werth N., Sandhoff R., Sandhoff K., and Proia R.L. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. 109 (2002) 1215-1221
15. Pelled D., Riebeling C., van Echten-Deckert G., Sandhoff K., and Futerman A.H. Reduced rates of axonal and dendritic growth in embryonic hippocampal neurones cultured from a mouse model of Sandhoff disease. Neuropathol. Appl. Neurobiol. 29 (2003) 341-349
16. Sango K., Yamanaka S., Hoffmann A., Okuda Y., Grinberg A., Westphal H., McDonald M.P., Crawley J.N., Sandhoff K., Suzuki K., and Proia R.L. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11 (1995) 170-176
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
18. Newburg D.S., Shea T.B., Yatziv S., Raghavan S.S., and McCluer R.H. Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells. Exp. Mol. Pathol. 48 (1988) 317-323
19. Yatziv S., Newburg D.S., Livni N., Barfi G., and Kolodny E.H. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition. J. Lab. Clin. Med. 111 (1988) 416-420
20. Trajkovic-Bodennec S., Bodennec J., and Futerman A.H. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells Mol. Dis. 33 (2004) 77-82
21. Kacher Y., Golan A., Pewzner-Jung Y., and Futerman A.H. Changes in macrophage morphology in a Gaucher disease model are dependent on CTP:phosphocholine cytidylyltransferase alpha. Blood Cells Mol. Dis. 39 (2007) 124-129
22. Liu Y., Suzuki K., Reed J.D., Grinberg A., Westphal H., Hoffmann A., Doring T., Sandhoff K., and Proia R.L. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2503-2508
23. Nagalakshmi M.L., Murphy E., McClanahan T., and de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int. Immunopharmacol. 4 (2004) 577-592
24. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815-3822
25. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
26. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., and Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96 (1995) 2339-2347
27. Pajkrt D., Camoglio L., Tiel-van Buul M.C., de Bruin K., Cutler D.L., Affrime M.B., Rikken G., van der Poll T., ten Cate J.W., and van Deventer S.J. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J. Immunol. 158 (1997) 3971-3977
28. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., and Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177 (1993) 547-550
29. Howard M., Muchamuel T., Andrade S., and Menon S. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177 (1993) 1205-1208
30. Muller W. Dissecting the cytokine network. Cell Immunol. 244 (2006) 162-164
31. Lo C.J., Fu M., Lo F.R., and Cryer H.G. Macrophage TNF mRNA expression induced by LPS is regulated by sphingomyelin metabolites. Shock 11 (1999) 411-415
32. Chiba N., Masuda A., Yoshikai Y., and Matsuguchi T. Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells. J. Cell. Physiol. 213 (2007) 126-136
33. Goldsmith M., Avni D., Levy-Rimler G., Mashiach R., Ernst O., Levi M., Webb B., Meijler M.M., Gray N.S., Rosen H., and Zor T. A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-alpha and induces interleukin-10 production in activated macrophages. Immunology (2008) 10.1111/j.1365-2567.2008.02928.x